Salesforce Friends ...
Health Care: Drugs
Columbia Laboratories Inc. (CBRX: NASDAQ)
$0.68 0.00 | 0.00%
06/04/12 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 0.68 |
| 52 Week High | 3.54 |
| 52 Week Low | 0.61 |
| Avg. Daily Vol. (Mil) | 0.63 |
| Beta (3 year) | 1.02 |
| Share Related Items | |
| Mkt Cap (Mil) | 59.38 |
| Shares Out (Mil) | 87.33 |
| Float (Mil) | 75.38 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.50 |
| Current Ratio | 5.50 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | 4.50 |
| Price/Sales | 1.73 |
| Price/Book | 2.28 |
| Price/Cash Flow | 2.20 |
| Per Share Data | |
| Earnings | 0.15 |
| Sales | 0.39 |
| Book Value | 0.30 |
| Cash Flow | 0.31 |
| Business Summary | |
|---|---|
| Columbia Laboratories, Inc. is in the business of developing, manufacturing and selling pharmaceutical products that utilize its proprietary bioadhesive drug delivery technologies. | |
| General Information | |
| 354 Eisenhower Parkway
Livingston, NJ 07039 |
|
| www.columbialabs.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 21 | |
| CEO: Mr. Frank C. Condella,Jr | |
| Short Interest | |
| Current Month (Mil) | 5.65 |
| Previous Month (Mil) | 5.21 |
| Short Interest Ratio (Days) | 12.30 |
| Management Effectiveness | |
| Return on Equity | 102.00 |
| Return on Assets | 77.90 |
| Return on Investments | 102.00 |
| Profitability | |
| Gross Margin | 66.50 |
| EBIT Margin | 77.70 |
| Profit Margin | 77.50 |
Portfolios with CBRX
- Portfolio NameUser Type
- UserMy Portfolio
- Contributor11 Stocks Under $4 With Upside
- Usermincronn Portfolio 1
- Usercscob Portfolio 1
- Userpharmer
- UserSUPRATRADE 2307070204
- UserSUPRATRADE VIRTUAL SKY
- Userstock fund
- UserBob700 Portfolio 1
- UserDunroamins
Latest CBRX Headlines from TheStreet
- A Classic Biotech Long Shot 04.05.12 | 09:04 am
- Columbia Stock Gaps Down On Today's Open (CBRX) 02.27.12 | 08:02 am
- These Drugs Stocks Will Win FDA Approval 02.16.12 | 12:02 pm
- Columbia Stock Soars (CBRX) 01.24.12 | 12:01 pm
- Columbia Stock Gaps Down On Today's Open (CBRX) 01.23.12 | 08:01 am
- Columbia Stock Gaps Up On Today's Open (CBRX) 01.18.12 | 08:01 am
- Columbia Laboratories Inc. Stock Upgraded (CBRX) 08.10.11 | 07:08 am
- 11 Stocks Under $4 With Upside: Analysts 05.11.11 | 12:05 pm
- Biotech Calendar: Key Dates for May 05.02.11 | 09:05 am
- Columbia Stock Falls On Unusually High Volume (CBRX) 04.06.11 | 02:04 pm
Press Releases for CBRX
- Columbia Laboratories Reports First Quarter 2012 Financial Results - Business Wire 05.04.12 | 06:05 am
- Columbia Laboratories Hires Cowen And Company To Assist In Evaluating Potential Strategic Transactions - Business Wire 03.13.12 | 06:03 am
- Columbia Laboratories Reports Fourth Quarter And Year-End 2011 Financial Results - Business Wire 03.08.12 | 06:03 am
- Columbia Laboratories Receives Nasdaq Minimum Bid Price Non-compliance Letter - Business Wire 03.06.12 | 04:03 pm
- Columbia Laboratories Announces 42% Workforce Reduction - Business Wire 03.01.12 | 04:03 pm
- Columbia Laboratories To Discuss Fourth Quarter And Year-End 2011 Financial Results On March 8, 2012, Conference Call - Business Wire 03.01.12 | 06:03 am
- Columbia Laboratories Will Present March 5th At Cowen And Company Health Care Conference - Business Wire 02.29.12 | 06:02 am
- Faruqi & Faruqi, LLP Announces Investigation Of Columbia Laboratories Inc. - PR Newswire 02.09.12 | 11:02 am
- The Law Firm Of Levi & Korsinsky Notifies Investors With Losses On Their Investment In Columbia Laboratories Inc. Of Class Action Lawsuit And The Deadline Of April 2, 2012 To Seek A Lead Plaintiff Position - Business Wire 02.02.12 | 02:02 pm
- Bronstein, Gewirtz & Grossman, LLC Investigates Columbia Laboratories, Inc. - Business Wire 01.23.12 | 10:01 am
Partner Headlines for CBRX
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- 12 Healthcare Companies Expecting Major February Catalysts - Seeking Alpha 02.01.12 | 07:02 am
- Market Losers - Benzinga 01.23.12 | 01:01 pm
- Columbia Labs Plummet after Recommendation Denial by FDA - Benzinga 01.23.12 | 09:01 am
- FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length - Benzinga 01.20.12 | 04:01 pm
- Watson Pharma and Columbia Labs Plunge on Proposed FDA Review - Benzinga 01.17.12 | 01:01 pm
- Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA - Benzinga 11.10.11 | 09:11 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 09.16.11 | 09:09 am
- Watson to Market Antares' OAB Drug - Analyst Blog - Zacks 07.12.11 | 10:07 am
- Upcoming PDUFA Dates for Sub-$5 Stocks - Seeking Alpha 07.05.11 | 09:07 am
